D-Plus Hemolytic Uremic Syndrome Overview

Save information for later
Sign Up

Learn About D-Plus Hemolytic Uremic Syndrome

What is the definition of D-Plus Hemolytic Uremic Syndrome?
D-plus (diarrhea positive) hemolytic uremic syndrome, also known as STEC hemolytic uremic syndrome, is a rare disease that affects children between one and ten years old which is characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia). D-plus hemolytic uremic syndrome develops after certain bacterial infections, such as Escherichia. coli (E. coli) that cause diarrhea.
What are the symptoms of D-Plus Hemolytic Uremic Syndrome?
Symptoms of D-plus hemolytic uremic syndrome can be mild or severe and usually appear after an illness that is characterized by fever, abdominal cramps and pain, nausea, vomiting, and bloody diarrhea (gastroenteritis). Symptoms of D-plus hemolytic uremic syndrome may include paleness, irritability, weakness, reduced urinary output or no urine, lethargy, acute kidney injury, chronic kidney disease, protein in the urine, unexplained bruising, nosebleeds, high blood pressure, gallstones, neurological deficits, confusion, partial paralysis, seizures, coma, pancreatitis, and diabetes mellitus.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Plus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous fluid and nutrition replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplantation.
Who are the top D-Plus Hemolytic Uremic Syndrome Local Doctors?
Elite in D-Plus Hemolytic Uremic Syndrome
Gianluigi Ardissino
Elite in D-Plus Hemolytic Uremic Syndrome
Gianluigi Ardissino
Milan, IT 

Gianluigi Ardissino practices in Milan, Italy. Mr. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

Elite in D-Plus Hemolytic Uremic Syndrome
Dr. Spero Cataland
Hematology
Elite in D-Plus Hemolytic Uremic Syndrome
Dr. Spero Cataland
Hematology

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
614-293-3737
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Spero Cataland is a Hematologist in Columbus, Ohio. Dr. Cataland is rated as an Elite provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in D-Plus Hemolytic Uremic Syndrome
Christoph B. Licht
Elite in D-Plus Hemolytic Uremic Syndrome
Christoph B. Licht
555 University Avenue, M5G 1X8, 
Toronto, ON, CA 

Christoph Licht practices in Toronto, Canada. Mr. Licht is rated as an Elite expert by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

View All Doctors
What are the latest D-Plus Hemolytic Uremic Syndrome Clinical Trials?
Diagnostic and Risk Criteria for Complement Defects in Thrombotic Microangiopathy and Amplifying Conditions, Such as Severe Hypertension: The COMPETE Study.
Diagnostic and Risk Criteria for Complement Defects in Thrombotic Microangiopathy and Amplifying Conditions, Such as Severe Hypertension: The COMPETE Study.
Enrollment Status: Recruiting
Publish Date: October 01, 2025

Summary: Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the etiological factor and this type of TMA is classified, according to the current nomenclature, as primary atypical hemolytic uremic syndrome (HUS). Half the...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Chinese Atypical Hemolytic Uremic Syndrome Patients
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Chinese Atypical Hemolytic Uremic Syndrome Patients
Enrollment Status: Recruiting
Publish Date: October 01, 2025

Summary: This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric and adult patients diagnosed with aHUS who will be treated according to routine clinical practice defined by local institutional treatment guidelines/protocol. Those aHUS patients who will be treated with a supportive therapy, which does not...

View All Clinical Trials